pyridine has been researched along with Neoplasms in 22 studies
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of cancer is increasing worldwide, affecting a vast majority of the human population, therefore, new different anticancer agents are being developed now and their safety still needs to be evaluated." | 2.82 | Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer. ( Kumar, A; Kumar, R; Majee, C; Mazumder, A; Mishra, R; Sahu, R, 2022) |
| " Since compound 1k displayed favorable bioavailability in mouse cassette dosing PK study, we conducted in vivo Pharmacodynamics (PD) studies of this compound." | 1.51 | Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor. ( Asano, M; Maezaki, H; Mizojiri, R; Nii, N; Sasaki, M; Satoh, Y; Sumi, H; Yamamoto, Y, 2019) |
| "ten times more cytotoxic against breast cancer (4T1) and human lung adenocarcinoma epithelial cells (A549) than a well-known anticancer drug, cisplatin." | 1.42 | The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells. ( Brindell, M; Kieda, C; Mazuryk, O; Suzenet, F, 2015) |
| "In particular, in colorectal cancer cells, expression of the cancer suppressor genes APC and p53 was increased following exposure to 6." | 1.40 | Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls. ( Chi, KW; Jeong, YJ; Jo, JH; Kang, SC; Lah, MS; Mishra, A, 2014) |
| "Compound 1 itself displays anticancer activity in HeLa, HepG2 and Jurkat cells with an enhancement on addition of the metal ions." | 1.37 | Impact of metal binding on the antitumor activity and cellular imaging of a metal chelator cationic imidazopyridine derivative. ( Chakravarthi, BV; Chakravarty, AR; Jayabaskaran, C; Karande, AA; Roy, M, 2011) |
| " Tumor growth inhibition was observed during the dosing interval, and the tumors regrew when compound administration was ceased." | 1.33 | Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. ( Bouska, JJ; de Jong, R; Giranda, VL; Gramling-Evans, EE; Guan, R; Han, EK; Johnson, EF; Klinghofer, V; Leverson, JD; Li, Q; Li, T; Liu, X; Luo, Y; Mamo, M; McGonigal, TP; Mika, AK; Mitten, MJ; Nguyen, PT; Oleksijew, A; Oltersdorf, T; Powlas, JA; Rosenberg, SH; Shi, Y; Shoemaker, AR; Smith, RA; Stoll, VS; Thomas, SA; Woods, KW; Zinker, BA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Saghatchi, F | 1 |
| Mohseni-Dargah, M | 1 |
| Akbari-Birgani, S | 1 |
| Saghatchi, S | 1 |
| Kaboudin, B | 1 |
| Sahu, R | 1 |
| Mishra, R | 1 |
| Kumar, R | 1 |
| Majee, C | 1 |
| Mazumder, A | 1 |
| Kumar, A | 1 |
| Mizojiri, R | 1 |
| Nii, N | 1 |
| Asano, M | 1 |
| Sasaki, M | 1 |
| Satoh, Y | 1 |
| Yamamoto, Y | 1 |
| Sumi, H | 1 |
| Maezaki, H | 1 |
| Zhang, D | 1 |
| Zhang, X | 1 |
| Ai, J | 1 |
| Zhai, Y | 1 |
| Liang, Z | 1 |
| Wang, Y | 2 |
| Chen, Y | 1 |
| Li, C | 1 |
| Zhao, F | 1 |
| Jiang, H | 1 |
| Geng, M | 1 |
| Luo, C | 1 |
| Liu, H | 1 |
| Reddy, MR | 1 |
| Reddy, PV | 1 |
| Kumar, YP | 1 |
| Srishailam, A | 1 |
| Nambigari, N | 1 |
| Satyanarayana, S | 2 |
| Mishra, A | 1 |
| Jeong, YJ | 1 |
| Jo, JH | 1 |
| Kang, SC | 1 |
| Lah, MS | 1 |
| Chi, KW | 1 |
| Adhami, F | 1 |
| Safavi, M | 1 |
| Ehsani, M | 1 |
| Ardestani, SK | 1 |
| Emmerling, F | 1 |
| Simyari, F | 1 |
| Davari, AS | 1 |
| Abnous, K | 1 |
| Mehri, S | 1 |
| Ghandadi, M | 1 |
| Hadizadeh, F | 1 |
| Mazuryk, O | 1 |
| Suzenet, F | 1 |
| Kieda, C | 1 |
| Brindell, M | 1 |
| Nagababu, P | 1 |
| Barui, AK | 1 |
| Thulasiram, B | 1 |
| Devi, CS | 1 |
| Patra, CR | 1 |
| Sreedhar, B | 1 |
| Gao, EJ | 1 |
| Sun, TD | 1 |
| Liu, SH | 1 |
| Ma, S | 1 |
| Wen, Z | 1 |
| Zhu, MC | 1 |
| Wang, L | 1 |
| Gao, XN | 1 |
| Guan, F | 1 |
| Guo, MJ | 1 |
| Liu, FC | 1 |
| Tajima, H | 1 |
| Honda, T | 1 |
| Kawashima, K | 1 |
| Sasabuchi, Y | 1 |
| Yamamoto, M | 1 |
| Ban, M | 1 |
| Okamoto, K | 1 |
| Inoue, K | 1 |
| Inaba, T | 1 |
| Takeno, Y | 1 |
| Aono, H | 1 |
| Roy, M | 1 |
| Chakravarthi, BV | 1 |
| Jayabaskaran, C | 1 |
| Karande, AA | 1 |
| Chakravarty, AR | 1 |
| Kendall, JD | 2 |
| O'Connor, PD | 1 |
| Marshall, AJ | 1 |
| Frédérick, R | 2 |
| Marshall, ES | 2 |
| Lill, CL | 2 |
| Lee, WJ | 2 |
| Kolekar, S | 2 |
| Chao, M | 2 |
| Malik, A | 2 |
| Yu, S | 2 |
| Chaussade, C | 2 |
| Buchanan, C | 2 |
| Rewcastle, GW | 2 |
| Baguley, BC | 2 |
| Flanagan, JU | 2 |
| Jamieson, SM | 2 |
| Denny, WA | 2 |
| Shepherd, PR | 2 |
| Giddens, AC | 1 |
| Tsang, KY | 1 |
| Singh, R | 1 |
| KAPLAN, NO | 1 |
| GOLDIN, A | 1 |
| HUMPHREYS, SR | 1 |
| CIOTTI, MM | 1 |
| VENDITTI, JM | 1 |
| BROMBACHER, PJ | 2 |
| EMMELOT, P | 2 |
| BECK, EG | 1 |
| SANTER, A | 1 |
| BROCKHAUS, A | 1 |
| STOCK, CC | 1 |
| BUCKLEY, S | 1 |
| SUGIURA, K | 1 |
| RHOADS, CP | 1 |
| Luo, Y | 1 |
| Shoemaker, AR | 1 |
| Liu, X | 1 |
| Woods, KW | 1 |
| Thomas, SA | 1 |
| de Jong, R | 1 |
| Han, EK | 1 |
| Li, T | 1 |
| Stoll, VS | 1 |
| Powlas, JA | 1 |
| Oleksijew, A | 1 |
| Mitten, MJ | 1 |
| Shi, Y | 1 |
| Guan, R | 1 |
| McGonigal, TP | 1 |
| Klinghofer, V | 1 |
| Johnson, EF | 1 |
| Leverson, JD | 1 |
| Bouska, JJ | 1 |
| Mamo, M | 1 |
| Smith, RA | 1 |
| Gramling-Evans, EE | 1 |
| Zinker, BA | 1 |
| Mika, AK | 1 |
| Nguyen, PT | 1 |
| Oltersdorf, T | 1 |
| Rosenberg, SH | 1 |
| Li, Q | 1 |
| Giranda, VL | 1 |
| Singh, P | 1 |
| Kaur, P | 1 |
| Luxami, V | 1 |
| Kaur, S | 1 |
| Kumar, S | 1 |
2 reviews available for pyridine and Neoplasms
| Article | Year |
|---|---|
Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer.
Topics: Antineoplastic Agents; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyridin | 2022 |
Pyridine.
Topics: Animals; Carcinogenicity Tests; Carcinogens; Disease Models, Animal; Environmental Exposure; Female; | 2000 |
20 other studies available for pyridine and Neoplasms
| Article | Year |
|---|---|
Cancer Therapy and Imaging Through Functionalized Carbon Nanotubes Decorated with Magnetite and Gold Nanoparticles as a Multimodal Tool.
Topics: Contrast Media; Ferrosoferric Oxide; Gold; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging | 2020 |
Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Topics: Acetyl-CoA Carboxylase; Administration, Oral; Amides; Animals; Drug Design; Enzyme Inhibitors; HCT11 | 2019 |
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Moveme | 2013 |
Synthesis, characterization, DNA binding, light switch "on and off", docking studies and cytotoxicity, of ruthenium(II) and cobalt(III) polypyridyl complexes.
Topics: Anti-Bacterial Agents; Bacteria; Cell Survival; Cobalt; DNA; Intercalating Agents; Light; Magnetic R | 2014 |
Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cymenes; Gene Exp | 2014 |
Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(II) complexes.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Coordination Complexes; Copper; | 2014 |
Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors.
Topics: Antineoplastic Agents; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; Phosphodiesterase 3 Inhibitors; P | 2014 |
The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.
Topics: Animals; Apoptosis; Cell Adhesion; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cisplatin; | 2015 |
Antiangiogenic activity of mononuclear copper(II) polypyridyl complexes for the treatment of cancers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; C | 2015 |
Synthesis, characterization, interaction with DNA and cytotoxicity in vitro of novel pyridine complexes with Zn(II).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Crystallography, X-R | 2010 |
Pyridylmethylthio derivatives as VEGF inhibitors. Part 1.
Topics: Anilides; Animals; Arthritis, Experimental; Cell Line; Choroidal Neovascularization; Disease Models, | 2010 |
Impact of metal binding on the antitumor activity and cellular imaging of a metal chelator cationic imidazopyridine derivative.
Topics: Antineoplastic Agents; Apoptosis; Cations; Cell Line, Tumor; Chelating Agents; DNA Cleavage; Fluores | 2011 |
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Binding Sites; Cell Li | 2012 |
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Binding Sites; Cell Li | 2012 |
Significance of enzymatically catalyzed exchange reactions in chemotherapy.
Topics: Animals; Coenzymes; Liver; Mice; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Pyridines; Tryptop | 1954 |
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA | 1956 |
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA | 1956 |
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA | 1956 |
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA | 1956 |
[BIOCHEMICAL STUDY OF THE EFFECT OF THE CYTOSTATIC QUARTZ ACTION THROUGH 3 LOW-MOLECULAR PYRIDINE-N-OXIDE COMPOUNDS ON AN ESTABLISHED CELL STRAIN (L929)].
Topics: Antineoplastic Agents; Cytostatic Agents; Neoplasms; Neoplasms, Experimental; Nitrous Oxide; Pyridin | 1964 |
A comparison of the retardation of Sarcoma 180 by SK 1424, 3-Bis (beta-chloroethyl) aminomethyl-4-methoxymethyl-5-hydroxy-6-methyl-pyridine with that by HN2, Methylbis (beta-chloroethyl) amine.
Topics: Amines; Animals; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Pyridines; Sarcoma; Sarcoma | 1951 |
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Humans; Indazoles; Indoles; M | 2005 |
Syntheses and anti-cancer activities of 2-[1-(indol-3-yl-/pyrimidin-5-yl-/pyridine-2-yl-/quinolin-2-yl)-but-3-enylamino]-2-phenyl-ethanols.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Indoles; Molecu | 2007 |